These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26212044)

  • 61. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.
    Salmon-Ceron D; Arvieux C; Bourlière M; Cacoub P; Halfon P; Lacombe K; Pageaux GP; Pialoux G; Piroth L; Poizot-Martin I; Rosenthal E; Pol S; ; ; ;
    Liver Int; 2014 Jul; 34(6):869-89. PubMed ID: 24138548
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals and Direct Acting Antivirals.
    Cirrincione LR; Senneker T; Scarsi K; Tseng A
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):565-582. PubMed ID: 32479127
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treating hepatitis C in HIV-HCV coinfected patients.
    Tossing G
    Infection; 2002 Oct; 30(5):329-31. PubMed ID: 12420736
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
    Seden K; Back D; Khoo S
    J Antimicrob Chemother; 2010 Jun; 65(6):1079-85. PubMed ID: 20335191
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals.
    Zeremski M; Martinez AD; Talal AH
    Clin Infect Dis; 2014 Mar; 58(6):880-2. PubMed ID: 24336913
    [No Abstract]   [Full Text] [Related]  

  • 67. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.
    Patel N; Nasiri M; Koroglu A; Amin R; McGuey L; McNutt LA; Roman M; Miller C
    AIDS Res Hum Retroviruses; 2015 Feb; 31(2):189-97. PubMed ID: 25432275
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
    Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
    AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of Raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents.
    Taramasso L; Cenderello G; Riccardi N; Tunesi S; Di Biagio A
    New Microbiol; 2017 Oct; 40(4):227-233. PubMed ID: 28994443
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals.
    Klein MB; Rollet KC; Hull M; Cooper C; Walmsley S; Conway B; Pick N;
    Antivir Ther; 2013; 18(5):717-21. PubMed ID: 23211632
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity.
    Han H; Agarwal R; Martel-Laferriere V; Dieterich DT
    Clin Liver Dis; 2013 Nov; 17(4):657-70, ix. PubMed ID: 24099023
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An update on the treatment options for HBV/HCV coinfection.
    Sagnelli E; Sagnelli C; Macera M; Pisaturo M; Coppola N
    Expert Opin Pharmacother; 2017 Nov; 18(16):1691-1702. PubMed ID: 29081251
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):572-5. PubMed ID: 26524329
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Management of hepatitis C virus coinfection in HIV-infected persons.
    O'Leary JG; Chung RT
    AIDS Read; 2006 Jun; 16(6):313-6, 318-20. PubMed ID: 16795921
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
    Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
    J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.
    Khaykin P; Kotzerke P; Stephan C; Nisius G; Bickel M; Haberl A; Stürmer M; Kurowski M; Brodt R; von Hentig N
    Ther Drug Monit; 2014 Apr; 36(2):192-201. PubMed ID: 24632753
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Update on HIV/HCV coinfection.
    Soriano V; Vispo E; Fernandez-Montero JV; Labarga P; Barreiro P
    Curr HIV/AIDS Rep; 2013 Sep; 10(3):226-34. PubMed ID: 23832718
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hepatitis C and HIV Coinfection for Social Workers in Public Health, Medical and Substance Use Treatment Settings.
    Sims OT; Womack BG
    Soc Work Public Health; 2015; 30(4):325-35. PubMed ID: 25811121
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of hepatitis C with new fixed dose combinations.
    Soriano V; Fernandez-Montero JV; de Mendoza C; Benitez-Gutierrez L; Peña JM; Arias A; Barreiro P
    Expert Opin Pharmacother; 2017 Aug; 18(12):1235-1242. PubMed ID: 28644739
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfected patient on long-term maintenance methadone therapy.
    Gervasoni C; Peri AM; Cattaneo D; Baldelli S; Rizzardini G; Milazzo L
    Eur J Clin Pharmacol; 2015 Aug; 71(8):1027-8. PubMed ID: 26081063
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.